Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX3 | P56373 | 17/20 | 0.60 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | USP2 | O75604 | 1/20 | 0.49 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10116698 | 0.90 | P2RX3 (0.62) | P2RX3MEN1KMT2AKDM4ELMNA | |
| SCHEMBL10116876 | 0.87 | P2RX3 (0.59) | P2RX3MEN1KMT2AALDH1A1NPSR1 | |
| SCHEMBL10116922 | 0.87 | P2RX3 (0.61) | P2RX3MEN1KMT2AKDM4ELMNA | |
| SCHEMBL10117498 | 0.86 | P2RX3 (0.58) | P2RX3MEN1KMT2AKDM4ELMNA | |
| SCHEMBL10116828 | 0.85 | P2RX3 (0.56) | P2RX3MEN1KMT2AALDH1A1NPSR1 | |
| SCHEMBL10116812 | 0.83 | P2RX3 (0.58) | P2RX3MEN1KMT2AKDM4ELMNA | |
| SCHEMBL15139594 | 0.82 | SMN1; SMN2 (0.55) | P2RX3MEN1KMT2AALDH1A1NPSR1 | |
| SCHEMBL10116908 | 0.81 | P2RX3 (0.52) | P2RX3MEN1KMT2AALDH1A1 | |
| SCHEMBL10116832 | 0.81 | P2RX3 (0.58) | P2RX3MEN1KMT2AKDM4ELMNA | |
| SCHEMBL15139582 | 0.81 | P2RX3 (0.55) | P2RX3MEN1KMT2AKDM4ELMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8497263-B2 | Pyrrolinone derivative and pharmaceutical composition comprising the same | SHIONOGI & CO., LTD. (JP) | 2013-07-30 | — | — | US | disclosed |
| US-8101644-B2 | Pyrrolinone derivative and pharmaceutical composition comprising the same | SHIONOGI & CO., LTD. (JP) | 2012-01-24 | — | — | US | disclosed |
| US-20120010199-A1 | NOVEL PYRROLINONE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | KAI HIROYUKI (JP) | 2012-01-12 | — | — | US | disclosed |
| US-20100210632-A1 | NOVEL PYRROLINONE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | SHIONOGI & CO., LTD. (JP) | 2010-08-19 | — | — | US | disclosed |
| EP-2143713-A1 | NOVEL PYRROLINONE DERIVATIVE AND MEDICINAL COMPOSITION CONTAINING THE SAME | Shionogi&Co., Ltd. (JP) | 2010-01-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120010199-A1 | NOVEL PYRROLINONE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | P2RX3, P2RX2, P2RX1 | P2RX3 1/4885MEN1 3731/4885KMT2A 3720/4885 |
| US-20100210632-A1 | NOVEL PYRROLINONE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | P2RX3, P2RX2, P2RX1 | P2RX3 1/4885MEN1 3731/4885KMT2A 3720/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.